Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris.
The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax.
It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria.
The company was founded in 1996 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 3, 23 | -0.25 Increased by +24.24% | -0.31 Increased by +19.35% |
| May 9, 23 | -0.35 Increased by 0.00% | -0.42 Increased by +16.67% |
| Mar 16, 23 | -0.12 Increased by +81.82% | 0.09 Decreased by -233.33% |
| Nov 3, 22 | -0.38 Decreased by -2.70% | -0.29 Decreased by -31.03% |
| Aug 3, 22 | -0.33 Decreased by -265.00% | -0.34 Increased by +2.94% |
| May 4, 22 | -0.35 Increased by +10.26% | -0.35 |
| Mar 14, 22 | -0.66 Decreased by -10.00% | -0.41 Decreased by -60.98% |
| Nov 8, 21 | -0.37 Increased by +19.57% | -0.45 Increased by +17.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 38.06 M Increased by +38.13% | -14.55 M Increased by +34.06% | Decreased by -38.23% Increased by +52.26% |
| Mar 31, 23 | 29.21 M Increased by +28.32% | -20.14 M Increased by +8.88% | Decreased by -68.96% Increased by +28.99% |
| Dec 31, 22 | 72.63 M Increased by +147.89% | -7.16 M Increased by +77.81% | Decreased by -9.85% Increased by +91.05% |
| Sep 30, 22 | 27.84 M Increased by +29.90% | -25.27 M Decreased by -38.83% | Decreased by -90.75% Decreased by -6.87% |
| Jun 30, 22 | 27.55 M Decreased by -50.27% | -22.07 M Decreased by -327.13% | Decreased by -80.09% Decreased by -556.69% |
| Mar 31, 22 | 22.76 M Increased by +53.65% | -22.11 M Decreased by -20.50% | Decreased by -97.12% Increased by +21.58% |
| Dec 31, 21 | 29.30 M Increased by +96.42% | -32.25 M Decreased by -28.96% | Decreased by -110.09% Increased by +34.34% |
| Sep 30, 21 | 21.44 M Increased by +81.77% | -18.20 M Increased by +12.72% | Decreased by -84.91% Increased by +51.98% |